[1]
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014; 37(Suppl. 1): S81-90.
[2]
American Diabetes Association AD. Standards of medical care in diabetes-2018. Diabetes Care 2018; 41(Suppl. 1): 7-14.
[3]
Tao Z, Shi A, Zhao J. Epidemiological perspectives of diabetes. Cell Biochem Biophys 2015; 73: 181-5.
[4]
World Health Organization. Global Report on Diabetes 2016.
[5]
Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: Implications for care. Diabetes Care 2007; 30: 753-9.
[6]
Yang W, Dall TM, Halder P, et al. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013; 36(4): 1033-46.
[7]
Chawla A, Chawla R, Jaggi S. Microvascular and macrovascular complications in diabetes mellitus: Distinct or continuum. Indian J Endocrinol Metab 2016; 20: 546-51.
[8]
Danaei G, Finucane MM, Lu Y, et al. National, regional and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011; 378: 31-40.
[9]
Zhou B, Lu Y, Hajifathalian K, et al. NCD Risk Factor Collaboration. (NCD-RisC). Worldwide trends in diabetes since 1980: A pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 2016; 387: 1513-30.
[10]
Ogurtsova K, da Rocha Fernandes JD, et al. IDF diabetes atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 2017; 128: 40-50.
[11]
Merry AHH, Erkens PMG, Boer JMA, et al. Co-occurrence of metabolic factors and the risk of coronary heart disease: A prospective cohort study in the Netherlands. Int J Cardiol 2012; 155(2): 223-9.
[12]
Merry AH, Erkens PMG, Boer JM, et al. Co-occurrence of metabolic factors and the risk of coronary heart disease: A prospective cohort study in the Netherlands. Int J Cardiol 2012; 155: 223-9.
[13]
Arrieta F, Piñera M, Iglesias P, et al. Metabolic control and chronic complications during a 3-year follow-up period in a cohort of type 2 diabetic patients attended in primary care in the Community of Madrid (Spain). Endocrinol y Nutr 2014; 61: 11-7.
[14]
Jiwani A, Marseille E, Lohse N, et al. Gestational diabetes mellitus: results from a survey of country prevalence and practices. J Matern Neonatal Med 2012; 25: 600-10.
[15]
Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives. Nat Rev Endocrinol 2012; 8: 228-36.
[16]
Zimmet PZ, Magliano DJ, Herman WH, et al. Diabetes: A 21st century challenge. Lancet Diabetes Endocrinol 2014; 2: 56-64.
[17]
Tamayo T, Rosenbauer J, Wild SH, et al. Diabetes in Europe: An update. Diabetes Res Clin Pract 2014; 103: 206-17.
[18]
Moradi-Lakeh M, Forouzanfar MH, El Bcheraoui C, et al. High fasting plasma glucose, diabetes and its risk factors in the eastern mediterranean region, 1990–2013: Findings from the global burden of disease study 2013. Diabetes Care 2017; 40: 22-9.
[19]
Forouhi NG, Wareham NJ. Epidemiology of diabetes. Medicine (Abingdon) 2014; 42: 698-702.
[20]
Hu FB. Globalization of Diabetes: The role of diet, lifestyle and genes. Diabetes Care 2011; 34: 1249-57.
[21]
Sayeed MA, Ali L, Hussain MZ, et al. Effect of socioeconomic risk factors on the difference in prevalence of diabetes between rural and urban populations in Bangladesh. Diabetes Care 1997; 20: 551-5.
[22]
Dagenais GR, Gerstein HC, Zhang X, et al. Variations in diabetes prevalence in low-, middle-, and high-income countries: Results from the prospective urban and rural epidemiological study. Diabetes Care 2016; 39: 780-7.
[23]
Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010; 464: 1293-300.
[24]
Vehik K, Hamman RF, Lezotte D, et al. Trends in high-risk HLA susceptibility genes among Colorado youth with type 1 diabetes. Diabetes Care 2008; 31: 1392-6.
[25]
Wilkin TJ. The accelerator hypothesis: Weight gain as the missing link between type I and type II diabetes. Diabetologia 2001; 44: 914-22.
[26]
Cardwell CR, Stene LC, Joner G, et al. Birthweight and the risk of childhood-onset type 1 diabetes: A meta-analysis of observational studies using individual patient data. Diabetologia 2010; 53: 641-51.
[27]
Cardwell CR, Stene LC, Joner G, et al. Maternal age at birth and childhood type 1 diabetes: A pooled analysis of 30 observational studies. Diabetes 2010; 59: 486-94.
[28]
Hara N, Alkanani AK, Ir D, et al. The role of the intestinal microbiota in type 1 diabetes. Clin Immunol 2013; 146: 112-9.
[29]
Willi C, Bodenmann P, Ghali WA, et al. Active smoking and the risk of type 2 diabetes. JAMA 2007; 298: 2654-64.
[30]
Gillies CL, Abrams KR, Lambert PC, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: Systematic review and meta-analysis. BMJ 2007; 334: 299.
[31]
Bellamy L, Casas J-P, Hingorani AD, et al. Type 2 diabetes mellitus after gestational diabetes: A systematic review and meta-analysis. Lancet 2009; 373: 1773-9.
[32]
Morris AP, Voight BF, Teslovich TM, et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet 2012; 44: 981-90.
[33]
Herder C, Kowall B, Tabak AG, et al. The potential of novel biomarkers to improve risk prediction of type 2 diabetes. Diabetologia 2014; 57: 16-29.
[34]
Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
[35]
Nathan DM, Barrett-Connor E, Crandall JP, et al. Long-term effects
of lifestyle intervention or metformin on diabetes development
and microvascular complications over 15-year follow-up: The
diabetes prevention program outcomes study. lancet Diabetes Endocrinol 2015; 3: 866-75.
[36]
Bray GA, Edelstein SL, Crandall JP, et al. Long-term safety, tolerability and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 2012; 35: 731-7.
[37]
Mann DM, Carson AP, Shimbo D, et al. Impact of A1C screening criterion on the diagnosis of pre-diabetes among U.S. Adults. Diabetes Care 2010; 33: 2190-5.
[38]
Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. Population in 1988-2006. Diabetes Care 2010; 33: 562-8.
[39]
Olson DE, Rhee MK, Herrick K, et al. Screening for diabetes and pre-diabetes with proposed A1C-based diagnostic criteria. Diabetes Care 2010; 33: 2184-9.
[40]
Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, et al. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): A cluster-randomised controlled trial. Lancet 2012; 380: 1741-8.
[41]
Herman WH, Ye W, Griffin SJ, et al. Early detection and treatment of type 2 diabetes reduce cardiovascular morbidity and mortality: A simulation of the results of the anglo-danish-dutch study of intensive treatment in people with screen-detected diabetes in primary care (ADDITION-Europe). Diabetes Care 2015; 38: 1449-55.
[42]
Food and Argicultrure Organization of the United Nations. Fats and fatty acids in human nutrition: Report of an expert consultation. FAO Food Nutr Pap 2010; 91: 1-166.
[43]
Ley SH, Hamdy O, Mohan V, et al. Prevention and management of type 2 diabetes: Dietary components and nutritional strategies. Lancet 2014; 383: 1999-2007.
[44]
Hayes C, Kriska A. Role of Physical Activity in Diabetes Management and Prevention. J Am Diet Assoc 2008; 108: S19-23.
[45]
Chiang JL, Kirkman MS, Laffel LMB, et al. Type 1 diabetes sourcebook authors. Type 1 diabetes through the life span: A position statement of the American diabetes association. Diabetes Care 2014; 37: 2034-54.
[46]
Inzucchi SE, Bergenstral RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140-9.
[47]
Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta-analysis. Lancet 2016; 387: 957-67.
[48]
Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575-85.
[49]
Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
[50]
Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: The Treating to New Targets (TNT) study. Diabetes Care 2006; 29: 1220-6.
[51]
World Health Organization. Global Action Plan for the Prevention and Control of NCDs 2013-2020. WHO 2015.
[52]
Mishra SR, Sharma A, Kaplan WA, et al. Liberating data to combat NCDs. lancet Diabetes Endocrinol 2016; 4: 482-3.
[53]
Zimmet P, Alberti KG, Magliano DJ, et al. Diabetes mellitus statistics on prevalence and mortality: Facts and fallacies. Nat Rev Endocrinol 2016; 12: 616-22.
[54]
Akerblom HK, Ballard DJ, Bauman B, et al. Geographic patterns of childhood insulin-dependent diabetes mellitus. Diabetes 1988; 37(8): 1113-9.
[55]
Karvonen M, Viik-Kajander M, Moltchanova E, et al. Incidence of childhood type 1 diabetes worldwide. Diabetes Care 2000; 23: 1516-26.
[56]
Tuomi T, Santoro N, Caprio S, et al. The many faces of diabetes: A disease with increasing heterogeneity. Lancet 2014; 383: 1084-94.
[57]
World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO consultation. 2010, Part 1: 1-20.
[58]
Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia Report of a WHO/IDF consultation 2006: 1-50.
[59]
Harjutsalo V, Sjöberg L, Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: A cohort study. Lancet 2008; 371: 1777-82.
[60]
Makaroff LE, Cavan D. Which biochemical assay is best for measuring diabetes prevalence? Lancet Diabetes Endocrinol 2015; 3: 582-3.
89
13